1. Pink Sheet
  2. >>Product Reviews

Janssen’s Multiple Myeloma Gene Therapy On Track For EU-Wide Approval

CHMP Recommends Six Extensions Of Indications For Approved Medicines

 
• By Vibha Sharma

The European Medicines Agency’s human medicines committee has recommended five new drugs for use in the EU at its latest monthly meeting.

Multiple myeloma cells emitting M (Monoclonal) protein in the blood flow - isometric view 3d illustration
Multiple myeloma is an incurable blood cancer that starts in the bone marrow • Source: Alamy

Janssen’s gene therapy for multiple myeloma patients, Carvykti (ciltacabtagene autoleucel), has been recommended for conditional EU-wide approval.

Carvykti is a CAR-T therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Product Reviews

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

US FDA Advisory Committee Misperceptions Abound … At HHS

 
• By Michael McCaughan

HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.

US FDA Layoffs Hit Conflict-Of-Interest Screening For ODAC Meeting

 
• By Sue Sutter and Derrick Gingery

Screening for conflicts and finding the right expertise for a two-day Oncologic Drugs Advisory Committee meeting on four products has been complicated by the Trump Administration’s initial communications freeze and subsequent layoffs in CDER.